Anup Roy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anup Roy has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Chinmay Kumar Panda
Department of Oncogene Regulation, Chittaranjan National Cancer Institute, Kolkata, India
5 shared publications - Saimul Islam
Department of Oncogene Regulation, Chittaranjan National Cancer Institute, 37, S.P. Mukherjee Road, Kolkata, West Bengal 700026, India
3 shared publications - Susanta Roychoudhury
Cancer Biology and Inflammatory Disorder Division CSIR‐Indian Institute of Chemical Biology Kolkata India
3 shared publications - Atish Barua
Department of Cancer Chemoprevention, Chittaranjan National Cancer Institute, Kolkata-700026, India
2 shared publications - Debolina Pal
Department of Oncogene Regulation, Chittaranjan National Cancer Institute, Kolkata, India
2 shared publications - Hemantika Dasgupta
Department of Oncogene Regulation, Chittaranjan National Cancer Institute, Kolkata, India
2 shared publications
Latest Publications
- Open Access
- 12 December 2024
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 480 (5) , 3221
Editorial Expression of Concern: Induction of HRR genes and inhibition of DNMT1 is associated with anthracycline anti-tumor antibiotic-tolerant breast carcinoma cells
- 12 December 2024
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 480 (5) , 3221
Open AccessEditorial Expression of Concern: Induction of HRR genes and inhibition of DNMT1 is associated with anthracycline anti-tumor antibiotic-tolerant breast carcinoma cells
- 27 November 2023
- Published by Springer Nature in Reproductive Sciences
- Vol. 31 (4) , 1122-1138
Down-regulation of FA-BRCA Pathway in Cervical Carcinoma Gradually Reversed During the Development of Chemo-tolerance: Clinical Implications
Cervical cancer is one of the leading causes of cancer death among females, worldwide. The contributory role of different cellular pathways in the process of carcinogenesis is still poorly understood. Our study was focused here to understand the functional evaluation of key regulatory genes of FA-BRCA pathway in the development of CACX and their role in chemo-tolerance of the disease by analyzing the molecular profile of the genes both in normal and tumour tissue of our sample pool, also validated in in silico datasets. Later on, prognostic importance of the genes was further evaluated in plasma DNA and cisplatin-treated in vitro system. We found that expression profile of FA-BRCA pathway genes was gradually reduced from undifferentiated basal-parabasal layers of normal tissue towards the progression of the disease. Further analysis revealed that frequent promoter methylation [32–55%] and deletion [34–52%] events were the plausible reasons for their reduced expression in CACX. Noticeably, invasion of promoter methylation of the genes [11–17%] in plasma CTCs of CACX patients was positively correlated [p < 0.001] with poor prognosis among patients. On the other hand, functional upregulation of these genes at higher concentrations [IC50–70] of cisplatin was a predictor for the development of drug tolerance, as evaluated in our in vitro study. This finding was supported further by low prevalence of γ-H2X foci formation and reduced expression of DNMT1 at higher concentrations of cisplatin. In totality, we discovered that the FA-BRCA pathway must be inactivated for cancer formation. In contrast, elevated gene expression played a substantial role in building of chemo-tolerance and might be associated with developing increased risk of disease recurrence among patients. Graphical Abstract Schematic diagram illustrating the gradual changes in the molecular profile of FA-BRCA pathway genes from different layers of normal epithelium towards the disease development and its role in development of chemo-tolerance of the disease
- 27 November 2023
- Published by Springer Nature in Reproductive Sciences
- Vol. 31 (4) , 1122-1138
Down-regulation of FA-BRCA Pathway in Cervical Carcinoma Gradually Reversed During the Development of Chemo-tolerance: Clinical Implications
Cervical cancer is one of the leading causes of cancer death among females, worldwide. The contributory role of different cellular pathways in the process of carcinogenesis is still poorly understood. Our study was focused here to understand the functional evaluation of key regulatory genes of FA-BRCA pathway in the development of CACX and their role in chemo-tolerance of the disease by analyzing the molecular profile of the genes both in normal and tumour tissue of our sample pool, also validated in in silico datasets. Later on, prognostic importance of the genes was further evaluated in plasma DNA and cisplatin-treated in vitro system. We found that expression profile of FA-BRCA pathway genes was gradually reduced from undifferentiated basal-parabasal layers of normal tissue towards the progression of the disease. Further analysis revealed that frequent promoter methylation [32–55%] and deletion [34–52%] events were the plausible reasons for their reduced expression in CACX. Noticeably, invasion of promoter methylation of the genes [11–17%] in plasma CTCs of CACX patients was positively correlated [p < 0.001] with poor prognosis among patients. On the other hand, functional upregulation of these genes at higher concentrations [IC50–70] of cisplatin was a predictor for the development of drug tolerance, as evaluated in our in vitro study. This finding was supported further by low prevalence of γ-H2X foci formation and reduced expression of DNMT1 at higher concentrations of cisplatin. In totality, we discovered that the FA-BRCA pathway must be inactivated for cancer formation. In contrast, elevated gene expression played a substantial role in building of chemo-tolerance and might be associated with developing increased risk of disease recurrence among patients. Graphical Abstract Schematic diagram illustrating the gradual changes in the molecular profile of FA-BRCA pathway genes from different layers of normal epithelium towards the disease development and its role in development of chemo-tolerance of the disease
- 22 December 2020
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 12 (3) , 1063-1078
Eugenol emerges as an elixir by targeting β-catenin, the central cancer stem cell regulator in lung carcinogenesis: anin vivoandin vitrorationale
According to population-based studies, lung cancer has become one of the leading causes of death globally in males and is also rising in females at an alarming rate. The aim of this study was to exploit the inherent properties of eugenol to restrict the growth of cancer cells in a tobacco-related human carcinogen NDEA-induced lung carcinogenesis model in vivo as a chemopreventive agent. More precisely, by utilizing its abundance in nature, eugenol (a component of clove) was utilized to establish the molecular mechanism of chemoprevention in the NDEA-induced mouse lung carcinogenesis model in a substantial cost-effective manner and was validated in the A549 human lung cancer cell line. Our study especially targeted the tiny, drug-resistant, and most virulent subpopulation of cancer cells called CSCs by targeting their regulator molecule β-catenin. The non-toxic dosage of eugenol was shown to enhance apoptosis, simultaneously suppressing cell proliferation in the lung tissue of carcinogen-treated mice without affecting the normal mice. Combining cellular apoptosis and proliferation, eugenol showed an exceptional chemopreventive potential in this lung carcinogenesis model. Importantly, eugenol strongly restricted the lung carcinoma in the mild dysplastic stage as a chemopreventive agent. The molecular analysis remarkably depicted the restriction of β-catenin nuclear transportation. The minimized total β-catenin pool and induced N-terminal Ser37 phosphorylation form after eugenol treatment resulted in its cytoplasmic degradation. Consequently, CSC markers such as CD44, Oct4, EpCAM, and Notcht1, whose expression is dependent on β-catenin decreased significantly, as proven by IHC, ICC, and WB analysis both in vivo and in vitro. The in vitro secondary sphere formation assay also proved the remarkably repressed CSC population, and hence the virulence. In another way, eugenol was proven to significantly enhance the degradation of β-catenin when treated with the CK1α inhibitor D4476 in vitro by Western blot. CK1α in the Wnt/β-catenin pathway plays a crucial role for tagging with the N-terminal Ser45 phosphorylation of β-catenin, which ultimately opens a position for the decisive phosphorylation by GSK3β at the Ser37 residue to take place. Thus, the conclusive extermination of CSCs achieved that was associated with recurrence due to treatment failure. That can help to achieve a longer and better quality of life in a natural, economical way.
- 22 December 2020
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 12 (3) , 1063-1078
Eugenol emerges as an elixir by targeting β-catenin, the central cancer stem cell regulator in lung carcinogenesis: anin vivoandin vitrorationale
According to population-based studies, lung cancer has become one of the leading causes of death globally in males and is also rising in females at an alarming rate. The aim of this study was to exploit the inherent properties of eugenol to restrict the growth of cancer cells in a tobacco-related human carcinogen NDEA-induced lung carcinogenesis model in vivo as a chemopreventive agent. More precisely, by utilizing its abundance in nature, eugenol (a component of clove) was utilized to establish the molecular mechanism of chemoprevention in the NDEA-induced mouse lung carcinogenesis model in a substantial cost-effective manner and was validated in the A549 human lung cancer cell line. Our study especially targeted the tiny, drug-resistant, and most virulent subpopulation of cancer cells called CSCs by targeting their regulator molecule β-catenin. The non-toxic dosage of eugenol was shown to enhance apoptosis, simultaneously suppressing cell proliferation in the lung tissue of carcinogen-treated mice without affecting the normal mice. Combining cellular apoptosis and proliferation, eugenol showed an exceptional chemopreventive potential in this lung carcinogenesis model. Importantly, eugenol strongly restricted the lung carcinoma in the mild dysplastic stage as a chemopreventive agent. The molecular analysis remarkably depicted the restriction of β-catenin nuclear transportation. The minimized total β-catenin pool and induced N-terminal Ser37 phosphorylation form after eugenol treatment resulted in its cytoplasmic degradation. Consequently, CSC markers such as CD44, Oct4, EpCAM, and Notcht1, whose expression is dependent on β-catenin decreased significantly, as proven by IHC, ICC, and WB analysis both in vivo and in vitro. The in vitro secondary sphere formation assay also proved the remarkably repressed CSC population, and hence the virulence. In another way, eugenol was proven to significantly enhance the degradation of β-catenin when treated with the CK1α inhibitor D4476 in vitro by Western blot. CK1α in the Wnt/β-catenin pathway plays a crucial role for tagging with the N-terminal Ser45 phosphorylation of β-catenin, which ultimately opens a position for the decisive phosphorylation by GSK3β at the Ser37 residue to take place. Thus, the conclusive extermination of CSCs achieved that was associated with recurrence due to treatment failure. That can help to achieve a longer and better quality of life in a natural, economical way.
- Retracted
- 1 January 2020
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 316, 108938
Eugenol restricts Cancer Stem Cell population by degradation of β-catenin via N-terminal Ser37 phosphorylation-an in vivo and in vitro experimental evaluation
- 1 January 2020
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 316, 108938
RetractedEugenol restricts Cancer Stem Cell population by degradation of β-catenin via N-terminal Ser37 phosphorylation-an in vivo and in vitro experimental evaluation
- 1 September 2016
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1862 (9) , 1472-1484
Frequent inactivation of MCC/CTNNBIP1 and overexpression of phospho-beta-catenin Y654 are associated with breast carcinoma: Clinical and prognostic significance
- 1 September 2016
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1862 (9) , 1472-1484
Frequent inactivation of MCC/CTNNBIP1 and overexpression of phospho-beta-catenin Y654 are associated with breast carcinoma: Clinical and prognostic significance
- 1 March 2016
- Published by Elsevier in Pathology - Research and Practice
- Vol. 212 (3) , 196-203
The stem cell renewal and DNA damage response pathways are frequently altered in fibroepithelial tumors of breast in Indian patients
- 1 March 2016
- Published by Elsevier in Pathology - Research and Practice
- Vol. 212 (3) , 196-203
The stem cell renewal and DNA damage response pathways are frequently altered in fibroepithelial tumors of breast in Indian patients
- 1 March 2005
- Published by Kamla Raj Enterprises in International Journal of Human Genetics
- Vol. 5 (1) , 49-55
Amplification of c-myc Locus is Independently Associated with the Deletions of Chromosome 8p in Breast Carcinoma
Attempts have been made in this study is to find out the mechanism of c-myc gene activation in breast carcinoma (CaBr) by analyzing alterations (rearrangement/amplification) in the ~580 Kb surroundings of this gene. The alteration in the c-myc locus was correlated with the deletions in chromosome (chr.) 8p to find if there is any association between the two phenomenons. The c-myc locus alteration was analyzed by Southern hybridization using the pal-1/ c-myc/ mlvi-4 probes. Overall, amplification in the c-myc locus was seen in 26% of the samples with 22% in the pal-1 region, 19% in the c-myc gene and 7% in the mlvi-4 region. This indicates that the c-myc gene activation may occur due to the amplification in the pal-1 region located 550 Kb 5’ and mlvi-4 region located 20 Kb 3’ of c-myc. About 42% of the samples showed loss of heterozygosity (LOH) in ≥ 40% of the microsatellite markers tested. Atleast 21% of the samples showed co-alterations in both arms of chr.8. No significant association was observed between the amplification in the c-myc locus and deletions in chr.8p. Thus the deletions in chr.8p and the amplification in the c-myc locus are independently associated with the development of CaBr.
- 1 March 2005
- Published by Kamla Raj Enterprises in International Journal of Human Genetics
- Vol. 5 (1) , 49-55
Amplification of c-myc Locus is Independently Associated with the Deletions of Chromosome 8p in Breast Carcinoma
Attempts have been made in this study is to find out the mechanism of c-myc gene activation in breast carcinoma (CaBr) by analyzing alterations (rearrangement/amplification) in the ~580 Kb surroundings of this gene. The alteration in the c-myc locus was correlated with the deletions in chromosome (chr.) 8p to find if there is any association between the two phenomenons. The c-myc locus alteration was analyzed by Southern hybridization using the pal-1/ c-myc/ mlvi-4 probes. Overall, amplification in the c-myc locus was seen in 26% of the samples with 22% in the pal-1 region, 19% in the c-myc gene and 7% in the mlvi-4 region. This indicates that the c-myc gene activation may occur due to the amplification in the pal-1 region located 550 Kb 5’ and mlvi-4 region located 20 Kb 3’ of c-myc. About 42% of the samples showed loss of heterozygosity (LOH) in ≥ 40% of the microsatellite markers tested. Atleast 21% of the samples showed co-alterations in both arms of chr.8. No significant association was observed between the amplification in the c-myc locus and deletions in chr.8p. Thus the deletions in chr.8p and the amplification in the c-myc locus are independently associated with the development of CaBr.